The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The category of IFG was introduced in the late 1990s to denote a state of non-diabetic hyperglycaemia defined by a fasting plasma glucose (FPG) concentration between 6.1 and 6.9 mmol/l. In 2003 the American Diabetes Association recommended that this diagnostic threshold be lowered to 5.6 mmol/l. The justification for lowering the threshold has been questioned. This simple change in cut-off value creates a pandemic of IFG, with a two- to five-fold increase in the prevalence of IFG across the world. Such a change in threshold has far-reaching public health implications. The European Diabetes Epidemiology Group (EDEG) has reviewed the evidence for this lower cut-off point for the definition of IFG and concludes that the previous definition should not be altered. EDEG further recommends that the value of all categorical definitions of non-diabetic hyperglycaemia should be reconsidered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“diabetes in people with IGT [20–23].”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“diabetes in people with IGT [20–23].”
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784 · cited 1×
“For example, we do not yet know the total benefit or the total cost to an individual who is designated at risk for diabetes by either test, by any criterion’ [1].”
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 1×
“diabetes in people with IGT [20–23].”
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 12×
“The relationship between levels of fasting glucose and future risk of diabetes A considerable amount of attention in the literature has been paid to comparisons between IFG and IGT and the relative merits of one compared with the other in predicting future diabetes [2, 3].”
InfluentialLevitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668 · cited 1×
“However, the association with fasting glucose was non-linear, with a possible threshold effect at around 5.6 mmol/l [ 12 ].”
Influential[The Da Qing IGT and Diabetes study].
Ayame, H. (2005) · PubMed · Cited by 658
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613 · cited 1×
“Nearly identical findings were reported from the Dutch Hoorn study, in which the age- and sex-adjusted RR for CVD mortality was 1.43 (0.79–2.60) in the FPG group 6.1– 6.9 mmol/l, but 0.63 (0.34–1.19) in the new IFG group of 5.6–6.0 mmol/l [ 14 ].”
InfluentialSelf-citationThe Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572 · cited 1×
“In contrast, a recent report of the US Diabetes Prevention Program (DPP) did not replicate this finding for metformin, but there was a risk reduction in hypertension with intensive lifestyle intervention [25].”
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360
“This change has been contentious and has not been accepted by all organizations (19,38).”
Huang, Y., Cai, X., Mai, W., Li, M., & Hu, Y. (2016) · BMJ · doi:10.1136/bmj.i5953 · Cited by 1,012
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“profile [6,52,138].”
BackgroundSelf-citationDefinition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome
Punthakee, Z., Goldenberg, R., & Katz, P. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.003 · Cited by 877
“Prediabetes (defined as a state which places individuals at high risk of developing diabetes and its complications) is diagnosed by any of the following criteria: a. IFG (FPG 6.1–6.9 mmol/L) [Grade A, Level 1 (45)] b. IGT (2hPG in a 75 g OGTT 7.8–11.0 mmol/L) [Grade A, Level 1 (45)] c. A1C 6.0%–6.4% (for use in adults…”
BackgroundInfluentialSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
“This change has been contentious and has not been accepted by all organizations (19,38).”
Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome
Goldenberg, R., & Punthakee, Z. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.011 · Cited by 611
Prediabetes diagnosis and treatment: A review
Bansal, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.296 · Cited by 579
The contribution of health behaviors to socioeconomic inequalities in health: A systematic review
Petrovic, D., de Mestral, C., Bochud, M., Bartley, M., Kivimäki, M., Vineis, P., Mackenbach, J., & Stringhini, S. (2018) · Preventive Medicine · doi:10.1016/j.ypmed.2018.05.003 · Cited by 503
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
“This change has been contentious and has not been accepted by all organizations (19,38).”
Forouhi, N. G., Luan, J., Hennings, S., & Wareham, N. J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02068.x · Cited by 262
Self-citationPrediabetes and the risk of cancer: a meta-analysis
Huang, Y., Cai, X., Qiu, M., Chen, P., Tang, H., Hu, Y., & Huang, Y. (2014) · Diabetologia · doi:10.1007/s00125-014-3361-2 · Cited by 234
“The lower threshold ADA definition of IFG released in 2003 resulted in a twofold to fivefold increase in the prevalence of IFG in most populations [5].”
BackgroundInfluentialRomero-Gómez, M., Fernández-Rodríguez, C. M., Andrade, R. J., Diago, M., Alonso, S., Planas, R., Solá, R., Pons, J. A., Salmerón, J., Barcena, R., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.022 · Cited by 185
Rathmann, W., Strassburger, K., Heier, M., Holle, R., Thorand, B., Giani, G., & Meisinger, C. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02863.x · Cited by 181
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 206
“This change has been contentious and has not been accepted by all organizations (19,38).”
The impact of liver fat vs visceral fat in determining categories of prediabetes
Kantartzis, K., Machann, J., Schick, F., Fritsche, A., Häring, H., & Stefan, N. (2010) · Diabetologia · doi:10.1007/s00125-010-1663-6 · Cited by 156
“0 mmol/l) [30, 31].”
Schoening, W. N., Buescher, N., Rademacher, S., Andreou, A., Kuehn, S., Neuhaus, R., Guckelberger, O., Puhl, G., Seehofer, D., & Neuhaus, P. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12384 · Cited by 136
Rijkelijkhuizen, J. M., Nijpels, G., Heine, R. J., Bouter, L. M., Stehouwer, C. D. A., & Dekker, J. M. (2007) · Diabetes Care · doi:10.2337/dc06-1238 · Cited by 120
“Because of such findings, the lower cutoff of the 2003 ADA criteria for IFG has been questioned (21,22).”
BackgroundSelf-citationAssociations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis
Huang, Y., Cai, X., Chen, P., Mai, W., Tang, H., Huang, Y., & Hu, Y. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.955051 · Cited by 111
Impaired fasting glucose prevalence in two nationwide cohorts of obese children and adolescents
Hagman, E., Reinehr, T., Kowalski, J. H., Ekbom, A., Marcus, C., & Holl, R. W. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.124 · Cited by 109
Diabetes mellitus after kidney transplantation: a French multicentre observational study
Kamar, N., Mariat, C., Delahousse, M., Dantal, J., Al Najjar, A., Cassuto, E., Lefrancois, N., Cointault, O., Touchard, G., Villemain, F., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm011 · Cited by 97
“European Diabetes Epidemiology group suggested that the initial ADA/WHO definition should not be altered [20].”
BackgroundMeisinger, C., Strassburger, K., Heier, M., Thorand, B., Baumeister, S. E., Giani, G., & Rathmann, W. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02905.x · Cited by 94
Lukaschek, K., Baumert, J., Kruse, J., Emeny, R. T., Lacruz, M. E., Huth, C., Thorand, B., Holle, R., Rathmann, W., Meisinger, C., et al. (2013) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.12.011 · Cited by 93
“9 mmol⁄ l) for the present analysis, as recommended by the European Diabetes Epidemiology Group [29].”
MethodKowall, B., Rathmann, W., Straßburger, K., Heier, M., Holle, R., Thorand, B., Giani, G., Peters, A., & Meisinger, C. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9452-6 · Cited by 99
“We used the original IFG criteria (6.1–6.9 mmol/l) for the present analysis, as recommended by the European Diabetes Epidemiology Group [13].”
MethodInfluentialStöckl, D., Döring, A., Peters, A., Thorand, B., Heier, M., Huth, C., Stöckl, H., Rathmann, W., Kowall, B., & Meisinger, C. (2011) · Diabetologia · doi:10.1007/s00125-011-2410-3 · Cited by 100
“9 mmol/l) for the present analysis, as recommended by the European Diabetes Epidemiology Group [23].”
MethodInfluentialBurr, J. F., Rowan, C. P., Jamnik, V., & Riddell, M. C. (2010) · The Physician and Sportsmedicine · doi:10.3810/psm.2010.04.1764 · Cited by 105
Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes
Ioannou, G. N., Bryson, C. L., & Boyko, E. J. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2006.07.005 · Cited by 86
Leung, C. W., Willett, W. C., & Ding, E. L. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012294 · Cited by 89
The Prediabetic Period: Review of Clinical Aspects
Rhee, S. Y., & Woo, J. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.107 · Cited by 82
Evidence for current diagnostic criteria of diabetes mellitus
Kumar, R., Nandhini, L. P., Kamalanathan, S., Sahoo, J., & Vivekanadan, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.396 · Cited by 95
Rückert, I.-M., Heier, M., Rathmann, W., Baumeister, S. E., Döring, A., & Meisinger, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022932 · Cited by 70
“We used the original IFG criteria (110 to 125 mg/dl or 6.1 to 6.9 mmol/l respectively) for the present analysis, as recommended by the European Diabetes Epidemiology Group”
MethodInfluentialCorona, G., Rastrelli, G., Balercia, G., Lotti, F., Sforza, A., Monami, M., Forti, G., Mannucci, E., & Maggi, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02717.x · Cited by 69
Colagiuri, S. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.003 · Cited by 78
Jung, J. H., Song, G. G., Lee, Y. H., Kim, J., Hyun, M. H., & Choi, S. J. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000953 · Cited by 63
Deedwania, P., Patel, K., Fonarow, G. C., Desai, R. V., Zhang, Y., Feller, M. A., Ovalle, F., Love, T. E., Aban, I. B., Mujib, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.05.038 · Cited by 54
“The recent decrease of the FPG cutoff from 110 mg/dL to 100 mg/dL by the ADA to define impaired fasting glucose (IFG) may also help explain the observed non-significant associations between prediabetes and cardiovascular outcomes [25].”
BackgroundShimodaira, M., Niwa, T., Nakajima, K., Kobayashi, M., Hanyu, N., & Nakayama, T. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-14 · Cited by 63
“Other organizations, including the European Diabetes Epidemiology Group (EDEG) and the Japan Diabetes Society (JDS), have retained the original diagnostic range for IFG at FPG levels of 110– 125 mg/dL [21,22].”
BackgroundDetection of diabetic patients in people with normal fasting glucose using machine learning
Lv, K., Cui, C., Fan, R., Zha, X., Wang, P., Zhang, J., Zhang, L., Ke, J., Zhao, D., Cui, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03045-9 · Cited by 60
“Although it was questioned when the justification for lowering the threshold of normal fasting glucose recommended by ADA [34], the warning line of normal fasting glucose needs timely adjustment for people from different races or regions considering the significant difference in diet, lifestyle,…”
BackgroundPlasma glucose levels as predictors of diabetes: the Mexico City diabetes study
Ferrannini, E., Massari, M., Nannipieri, M., Natali, A., López‐Ridaura, R., & Gonzales-Villalpando, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1289-8 · Cited by 44
“Rationale and value of the new IFG definition have been criticised [12].”
BackgroundAndreozzi, F., Succurro, E., Mancuso, M. R., Perticone, M., Sciacqua, A., Perticone, F., & Sesti, G. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.724 · Cited by 40
Meisinger, C., Döring, A., Stöckl, D., Thorand, B., Kowall, B., & Rathmann, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037180 · Cited by 35
“9 mmol/l) for the present analysis, as recommended by the European Diabetes Epidemiology Group [16].”
MethodInfluentialLooijmans, A., Jörg, F., Bruggeman, R., Schoevers, R. A., & Corpeleijn, E. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2310-5 · Cited by 34
“1 mmol/L [30] or receiving antihyperglycemic medication.”
Miettinen, M. H., Mäkelä, S., Ala-Houhala, I. O., Huhtala, H., Kööbi, T., Vaheri, A. I., Pasternack, A. I., Pörsti, I. H., & Mustonen, J. T. (2009) · Nephron Clinical Practice · doi:10.1159/000213899 · Cited by 34
Risk of Coronary Heart Disease in Different Criterion of Impaired Fasting Glucose: A Meta-Analysis
Xu, T., Liu, W., Cai, X., Ding, J., Tang, H., Huang, Y., & Hu, Y. (2015) · Medicine · doi:10.1097/md.0000000000001740 · Cited by 38
“Although more than a decade has passed, this change is still contentious and not adopted by the World Health Organization (WHO) Expert Group(6) or other international guidelines.(7,8) One of the main arguments against the cut-point of IFG proposed by 2003 ADA is that it greatly increases the number of subjects labeled…”
BackgroundPhysical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort
Byambasukh, O., Zelle, D. M., & Corpeleijn, E. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000168 · Cited by 35
“001 Liver blood tests ALT (U/L) 19 (14-27) 18 (13-24) 28 (20-39) <0.”
BackgroundInfluentialSomchob, B., Promphet, N., Rodthongkum, N., & Hoven, V. P. (2023) · Talanta · doi:10.1016/j.talanta.2023.125510 · Cited by 31
Zhuo, X., Zhang, P., Kahn, H. S., & Gregg, E. W. (2013) · Diabetes Care · doi:10.2337/dc13-0497 · Cited by 31
Jessup, R. L., Putrik, P., Buchbinder, R., Nezon, J., Rischin, K. J., Cyril, S., Shepperd, S., & O’Connor, D. A. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036112 · Cited by 38
Kato, M., Noda, M., Suga, H., Matsumoto, M., & Kanazawa, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1792 · Cited by 30
Cardiovascular disease and diabetes in people with severe mental illness
Binder, M. D., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(09)70031-7 · Cited by 27
Self-citationAmerican College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb11 · Cited by 26
Li, X., Xia, M., Ma, H., Hu, Y., Yan, H., He, W., Lin, H., Zhao, N., Gao, J., & Gao, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065210 · Cited by 26
Valdés, S., Botas, P., Delgado, E., Álvarez, F. V., & Cadórniga, F. D. (2008) · Metabolism · doi:10.1016/j.metabol.2007.10.017 · Cited by 29
“In its position statement, the EDEG states that the decision concerning where to draw a cutoff point on a continuous scale relates to the relative harm from being a false-positive compared with a false-negative and this in turn is dependent upon the treatment consequences that follow from attribution of a label [5].”
BackgroundLiu, S., Kim, E. D., Wu, A., Meyer, M. L., Cheng, S. C., Hoogeveen, R. C., Ballantyne, C. M., Tanaka, H., HEISS, G. M., Selvin, E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212892 · Cited by 27
Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave
Hert, M. D., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H. (2009) · Revista de Psiquiatría y Salud Mental · doi:10.1016/s1888-9891(09)70714-1 · Cited by 32
Self-citationDong, X., Zhou, L., Zhai, Y., Lü, B., Wang, D., Shi, H., Luo, X., Fan, W., & Hu, R. (2007) · Metabolism · doi:10.1016/j.metabol.2007.08.004 · Cited by 24
Katibeh, M., Hosseini, S., Soleimanizad, R., Manaviat, M. R., Kheiri, B., Khabazkhoob, M., Daftarian, N., & Dehghan, M. (2015) · Eastern Mediterranean Health Journal · doi:10.26719/2015.21.412 · Cited by 22
Fasting plasma glucose and Type 2 diabetes risk: a non‐linear relationship
Schulze, M. B., Fritsche, A., Boeing, H., & Joost, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02919.x · Cited by 22
Looijmans, A., Stiekema, A. P. M., Bruggeman, R., van der Meer, L., Stolk, R. P., Schoevers, R. A., Jörg, F., & Corpeleijn, E. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.199315 · Cited by 24
Self-citationFasting glucose cutoff point: where does the risk terminate? Tehran lipid and glucose study
Bozorgmanesh, M., Hadaegh, F., Saadat, N., & Azizi, F. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0298-5 · Cited by 22
“important is the shape of the risk curve relating levels of FPG to the future risk of incident diabetes [26].”
BackgroundSampson, M., Elwell-Sutton, T., Bachmann, M. O., Clark, A., Dhatariya, K., Ferns, C., Howe, A. C., John, W. G., Rayman, G. A., Swafe, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24662-y · Cited by 21
The Natural Course of Impaired Fasting Glucose
Święcicka-Klama, A., Połtyn–Zaradna, K., Szuba, A., & Zatońska, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_571 · Cited by 23
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.10.001 · Cited by 22
Jovanović, J., Šarac, I., Jovanović, S., Sokolovic, D. T., Govedarović, N., & Jovanović, J. (2019) · International Journal of Occupational Safety and Ergonomics · doi:10.1080/10803548.2019.1579458 · Cited by 22
Rhee, S. Y., Kim, J. Y., Chon, S., Hwang, Y., Jeong, I., Oh, S., Ahn, K. J., Chung, H. Y., Woo, J., Kim, S. W., et al. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.3.157 · Cited by 18
“However, the current diagnostic criteria for T2DM were established based on the risk of developing chronic microvascular complications [10-15].”
BackgroundThe threshold for definition of impaired fasting glucose in a Japanese population
Inoue, K., Matsumoto, M., & Akimoto, K. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02850.x · Cited by 17
“1 mmol/l in the IFG category creates a remarkably higher prevalence of IFG (three to four fold-increase) as concerned by EDEG [2] and JDA [3].”
BackgroundInfluentialHirata, A., Sugiyama, D., Kuwabara, K., Hirata, T., Tsutatani, H., Funamoto, M., Watanabe, K., Miyamatsu, N., & Okamura, T. (2018) · Hepatology Research · doi:10.1111/hepr.13065 · Cited by 18
American College of Endocrinology Pre-Diabetes Consensus Conference: Part One
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb10 · Cited by 20
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.10.012 · Cited by 25
Inoue, K., Inoue, M., Matsumoto, M., & Akimoto, K. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03536.x · Cited by 15
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.12.001 · Cited by 19
Bruins, J., Jörg, F., van den Heuvel, E. R., Bartels‐Velthuis, A. A., Corpeleijn, E., Muskiet, F. A. J., Pijnenborg, G. H. M., & Bruggeman, R. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.059 · Cited by 13
“…mmHg or being prescribed antihypertensives; 3) HDL-C b 1.30/1.03 mmol/l (female/male) or receiving lipid-lowering drugs; 4) triglycerides ≥ 1.7 mmol/l or receiving triglyceride-lowering drugs 3); 5) fasting glucose ≥ 6.1 mmol/l, being prescribed antidiabetics (Forouhi et al., 2006;WHO, 2006).”
BackgroundInfluentialJessup, R. L., O’Connor, D. A., Putrik, P., Rischin, K. J., Nezon, J., Cyril, S., Shepperd, S., & Buchbinder, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024385 · Cited by 16
Costa, B., Barrio, F., Bolíbar, B., & Castell, C. (2007) · Medicina Clínica · doi:10.1157/13102358 · Cited by 16
Consenso de Prediabetes. Documento de posición de la Asociación Latinoamericana de Diabetes (ALAD)
Rosas-Saucedo, J., Caballero, A. E., Brito-Córdova, G. X., Bruce, H. G., Costa-Gil, J., Lyra, R., & Rosas-Guzmán, J. (2017) · Alad · doi:10.24875/alad.17000307 · Cited by 42
Janssen, P. G. H., Gorter, K. J., Stolk, R. P., & Rutten, G. E. H. M. (2007) · Primary care diabetes · doi:10.1016/j.pcd.2007.02.001 · Cited by 12
Self-citationHarati, H., Hadaegh, F., Tohidi, M., & Azizi, F. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.04.006 · Cited by 13
When should screening be performed for gestational diabetes?
Guedjanne, A.-M. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.11.015 · Cited by 12
Classical cardiovascular risk factors according to fasting plasma glucose levels
Martínez‐Hervás, S., Romero, P., Hevilla, E. B., Real, J. T., Priego, A., Martin-Moreno, J. M., Carmena, R., & Ascaso, J. F. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.09.005 · Cited by 9
Diabetes Progression from "High-Normal" Glucose in School Teachers
Moriuchi, T., Oka, R., Yagi, K., Miyamoto, S., Nomura, H., Yamagishi, M., Mabuchi, H., Kobayashi, J., & Koizumi, J. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3513 · Cited by 10
“In 2003, the American Diabetes Association (ADA) reduced the lower limit of IFG from 110 mg/dL to 100 mg/dL to optimize the prediction of future type 2 diabetes (8), although this change has not been supported by the European Diabetes Epidemiology Group (EDEG) (9) and the last WHO/ International Diabetes Federation co…”
BackgroundBächle, C., Claessen, H., Andrich, S., Brüne, M., Dintsios, C., Slomiany, U., Roggenbuck, U., Jöckel, K., Moebus, S., & Icks, A. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000172 · Cited by 9
Back to the future—Do IGT and IFG have value as clinical entities?
Colagiuri, S., Borch‐Johnsen, K., & Wareham, N. J. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.07.001 · Cited by 14
Self-citationA Bayesian network model of new-onset diabetes in older Chinese: The Guangzhou biobank cohort study
Wang, Y., Zhang, W. S., Hao, Y. T., Jiang, C. Q., Jin, Y. L., Cheng, K. K., Lam, T. H., & Xu, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.916851 · Cited by 13
Risk for Future Diabetes among Individuals with High-normal Glycemia at 40 Years of Age
Kabeya, Y., Shimada, A., Yamasawa, F., Tomita, M., Katsuki, T., Oikawa, Y., & Atsumi, Y. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7926 · Cited by 9
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Atención Primaria · doi:10.1016/j.aprim.2014.12.002 · Cited by 35
Définition, classification et diagnostic du diabète, du prédiabète et du syndrome métabolique
Goldenberg, R., & Punthakee, Z. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.031 · Cited by 22
Sesti, G., Andreozzi, F., Bonadonna, R. C., Mattia, G. D., Leonetti, F., Luzi, L., Marini, M. A., Natali, A., Vettor, R., Bonora, E., et al. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.775 · Cited by 7
Mekonnen, B. A., Oumer, A., Ale, A., Hamza, A., Dagne, I., Umer, A. A., Fentie, D., Yigezu, M., Tariku, Z., & Abate, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283075 · Cited by 7
“For instance, an estimated 25% of IBG will progress to diabetes while 50% remain in an impaired state [19, 20] and increases cardiovascular mortality by 43% [21].”
BackgroundBrouwer, J., Wardenaar, K. J., Liemburg, E. J., Doornbos, B., Mulder, H., & Cath, D. C. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.042 · Cited by 6
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.10.008 · Cited by 13
“• Tener una glucemia basal < 110 mg/dl.”
Eligini, S., Porro, B., Werba, J. P., Capra, N., Genovese, S., Greco, A., Cavalca, V., & Banfi, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061407 · Cited by 7
Schöning, W., Neidel, N., Buescher, N., Andreou, A., Pascher, A., Seehofer, D., Bahra, M., Schmitz, V., Pratschke, J., & Puhl, G. (2015) · Clinical Transplantation · doi:10.1111/ctr.12520 · Cited by 6
“glucose levels (Gluc) >120 mg/dL, or oral antidiabetic treatment and insulin dependency were defined as “hyperglycemia” (HGLY) (21).”
BackgroundInfluentialDevelopment of hyperglycemia and diabetes in captive Polish bank voles
Bartelik, A., Cieśla, M., Kotlinowski, J., Bartelik, S., Czaplicki, D., Grochot‐Przeczek, A., Kurowski, K., Koteja, P., Dulak, J., & Józkowicz, A. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2012.12.006 · Cited by 6
Evidence for the Diagnosis of Metabolic Syndrome in Japan
Sugawara, A., & Sone, H. (2011) · The Japanese Journal of Nutrition and Dietetics · doi:10.5264/eiyogakuzashi.69.205 · Cited by 5
Wie häufig ist Typ-2-Diabetes in Deutschland?
Rathmann, W., & Meisinger, C. (2010) · Der Diabetologe · doi:10.1007/s11428-009-0496-8 · Cited by 5
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Avances en Diabetología · doi:10.1016/j.avdiab.2014.10.007 · Cited by 10
Bachmann, M. O., Lewis, G., John, W. G., Turner, J. J. O., Dhatariya, K., Clark, A., Pascale, M., Sampson, M., & Study, N. D. P. (2019) · Diabetic Medicine · doi:10.1111/dme.14111 · Cited by 6
Maladie cardiovasculaire et diabète chez les personnes atteintes d’une maladie mentale sévère
Scheen, A. J., Gillain, B., & Hert, M. D. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70021-3 · Cited by 9
Hert, M. A. F. D., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Møller, H. J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.08.001 · Cited by 6
“European [52] Farouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, et al.”
BackgroundSelf-citationWatanabe, Y., Eto, T., Taniguchi, S., & Terauchi, Y. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6583 · Cited by 4
“However, the European Diabetes Epidemiology Group (EDEG) proposed that the threshold be kept at 110 mg/dL because there was insufficient evidence to change the threshold to 100 mg/dL, and consensus regarding the identification of impaired FPG based on this change was lacking; the onset of impaired FPG was estimated to…”
BackgroundDefinition, Epidemiology and Classification of Diabetes and Structure of the Diabetes Team
Craig, M. E., Glastras, S. J., & Donaghue, K. C. (2007) · Wiley eBooks · doi:10.1002/9780470692271.ch2 · Cited by 6
Efectividad en la prevención de la diabetes tipo 2. Un aterrizaje forzoso en la realidad
Costa, B. (2008) · Medicina Clínica · doi:10.1157/13116576 · Cited by 5
Metadata
- Authors
- On behalf of, E. D. E. G., Forouhi, N. G., Balkau, B., Borch-Johnsen, K., Dekker, J., Glumer, C., Qiao, Q., Spijkerman, A., Stolk, R., Tabac, A., & Wareham, N. J.
- Affiliations
- MRC Elsie Widdowson Laboratory (GB)
- Inserm (FR)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University of Helsinki (FI)
- University Medical Center Groningen (NL)
- Corresponding author
- Wareham, N. J.
- Venue
- Diabetologia
- Published
- 2006-03-09
- Volume
- 49
- Issue
- 5
- Pages
- 822-827
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2126463294
- Semantic Scholar
- 24e9ce6a16ed005b7b6ec639d9a58ee46b82770e
- Cited by
- 140
- References
- 36
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 12 · 2014: 3 · 2013: 11 · 2012: 5
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- impaired fasting glucose, diagnostic thresholds, cut-off values, non-diabetic hyperglycaemia, fasting blood glucose, American Diabetes Association criteria, diagnostic criteria
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Diabetic Angiopathies, Europe, Fasting, Humans, Prevalence, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.